Cardinal Health account plan
Pharmaceuticals medical products distribution
At a glance
Cardinal Health distributes drugs and medical products in the US: $254.2 billion FY2026 revenue, about 63,900 employees.
Cardinal Health, headquartered in Dublin, Ohio, is a healthcare services and products company that distributes pharmaceuticals and medical products to hospitals, health systems, pharmacies, ambulatory surgery centers, laboratories, physician offices and patients at home. It also makes Cardinal Health brand medical products, runs physician-practice management organizations (MSOs), nuclear pharmacies, home diabetes supply and freight management. In the fiscal year to June 30, 2026, revenue was $254.2 billion (+14%), GAAP operating earnings $2,613 million (+15%) and non-GAAP diluted EPS $11.26 (+37%); almost all revenue is in the US. It had about 63,900 employees at June 30, 2026, and is listed on the NYSE (CAH).
Business units
Pharmaceutical and Specialty Solutions (Pharma)
about 92% of FY2026 segment revenue ($234,833 million)Branded, generic and OTC drug distribution to pharmacies and hospitals, specialty distribution, biopharma services, and the MSO platforms The Specialty Alliance (GI and urology) and Navista (oncology). FY2026 revenue rose 15% and profit 23% to $2,783 million; Specialty grew "over 25%". Led by Deborah Weitzman, CEO Pharma segment.
Global Medical Products and Distribution (GMPD)
about 5% of FY2026 segment revenue ($12,719 million)Manufactures and sources Cardinal Health brand products such as gloves, syringes, wound care, drapes and procedure kits, and distributes medical products in the US and Canada. FY2026 revenue was "relatively flat" (+1%) and profit rose 91% to $258 million, helped by the IEEPA tariff refund. Led by Stephen Mason, CEO GMPD segment.
at-Home Solutions
$4,536 million FY2026 revenueEdgepark and Advanced Diabetes Supply Group (ADS) supply patients with chronic conditions at home, and a B2B service delivers supplies for home medical equipment providers, home health and hospice agencies. Fill rate is nearly 99%.
Nuclear and Precision Health Solutions
$1,851 million FY2026 revenueNuclear pharmacies and facilities producing radiopharmaceuticals for imaging and theranostics. PET grew over 20% and theranostics nearly 30% in Q4 FY2026, and Actinium-225 production is being expanded.
OptiFreight Logistics
$405 million FY2026 revenueShipping and logistics optimisation for hospitals, pharmacies, labs and surgery centers, with new pharmacy shipment tracking tools.
Strategic priorities
- Specialty and biopharma growth
- Specialty grew over 25% in fiscal 2026 and planning assumes double-digit growth; Biopharma Solutions is targeted at $1 billion by 2028 with 20+% growth, and the 3PL now exclusively services nearly half the cell and gene market.
- Expand the MSO platforms
- The strategy is to expand the MSOs in GI, urology and oncology and the services they provide; M&A priorities are autoimmune and urology bolt-ons, and The Specialty Alliance reached 33 states.
- Grow Cardinal Health brand products
- The GMPD improvement plan continues, with Cardinal Health brand growing at least mid-single digits for six quarters and FY2027 GMPD profit guided at $200-220 million.
- Earnings growth above the long-term target
- FY2027 non-GAAP EPS guidance is $12.40 to $12.60 (+13% to +15%), above the 12% to 14% long-term target, with Other revenue growing 11% to 13%.
- Distribution automation
- Capex of about $700 million in FY2027 goes mainly to manufacturing and distribution infrastructure and technology, including a new Indianapolis distribution center with robotics opening in 2027.
Latest results
In Q4 FY2026 (quarter to June 30, 2026), revenue was $63.7 billion (+6%), non-GAAP operating earnings $935 million (+30%) and non-GAAP diluted EPS $2.91 (+40%), or $2.60 excluding a one-time $0.31 IEEPA tariff refund benefit. Pharma revenue was $58.8 billion with profit of $645 million (+21%); GMPD profit was $150 million, of which $100 million came from the tariff refund. For FY2027 the company guides to non-GAAP EPS of $12.40 to $12.60, about $1 billion of buybacks, about $700 million of capex and adjusted free cash flow of $3.5-4.0 billion. On October 1, 2026 it signed a binding letter of intent to extend its CVS Health distribution agreement through June 30, 2032, and reaffirmed that guidance.
Investments and deals
- MSO acquisitions
- ION (December 2024, $1.1 billion), GI Alliance (January 2025, about $2.8 billion), Urology America (May 2025, $381 million) and Solaris Health (November 2025, about $1.9 billion in cash), bringing more than 750 providers across more than 250 practice locations.
- Home diabetes supply
- ADS was acquired in April 2025 for about $1.0 billion; Strive Medical has been completed and AdaptHealth's Diabetes Health business is being acquired.
- Capex and distribution centers
- Capex was $649 million in FY2026 on automation, supply chain technology and platforms, with about $700 million expected in FY2027; new Indianapolis and Sacramento distribution centers are planned.
- Share buybacks
- $1.4 billion of buybacks in FY2026 and a new $5.0 billion authorisation approved on August 4, 2026, taking the total to $6.4 billion.
Challenges and risks
- Drug pricing policy
- The Inflation Reduction Act caps prices for certain drugs and reduces revenue, alongside the most-favored-nation order and tariffs on imported branded pharmaceuticals; distribution margins are about 1%.
- Customer concentration
- CVS Health was 28% of FY2026 revenue and the five largest customers 43%; members of Vizient and Premier GPOs were 29%.
- Tariffs and commodity costs
- GMPD still faces several tariff regimes, generics could face 100% tariffs from 2028, and a protracted Iran conflict raising fuel and resin costs would push GMPD profit to the low end.
- MSO regulation and integration
- Laws such as Oregon's restrict corporate ownership of physician practices, and the Navista oncology MSO took a $184 million goodwill impairment.
- Opioid settlements
- $4.3 billion is accrued for national opioid settlements, with most remaining payments through 2038.
What leadership says
“We have simplified our strategy, our structure and how we operate.”
“we are fairly large in that space, but we still represent a very small percentage of the market.”
“we're seeing the market voting for the equity arrangement”
“Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results.”
Where a supplier can help
- Warehouse automation and robotics
- Tied to the distribution automation priority and the roughly $700 million FY2027 capex: robotics, warehouse software and supply chain technology suppliers fit the new Indianapolis and Sacramento distribution centers.
- Physician-practice services
- Tied to MSO expansion: revenue cycle, practice software, compliance and integration services can help MSO platforms absorb acquired GI, urology and oncology practices.
- Cell and gene therapy logistics
- Tied to specialty and biopharma growth: cold-chain, specialty pharmacy and data tools support the 3PL and the cell and gene therapy pharmacy.
- Sourcing and cost resilience in GMPD
- Tied to tariff and commodity challenges: alternative sourcing, resin and fuel cost management and manufacturing efficiency suppliers help protect Cardinal Health brand margins.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Cardinal Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Cardinal Health Annual Report on Form 10-K, fiscal year ended June 30, 2026
- Cardinal Health (Ohio corporation formed in 1979, headquartered in Dublin, Ohio; fiscal year ends June 30) is a global healthcare services and products company serving hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. About 63,900 employees at June 30, 2026, of whom 18,100 outside the U.S. and 2,700 healthcare providers.
- FY2026 revenue $254.2 billion (+14%), gross margin $9.8 billion (+20%), GAAP operating earnings $2,613 million (+15%), non-GAAP operating earnings $3,624 million (+30%); GAAP diluted EPS $7.23 (+12%), non-GAAP diluted EPS $11.26 (+37%).
- Two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma", $234,833 million revenue, $2,783 million profit, +23%) and Global Medical Products and Distribution ("GMPD", $12,719 million, $258 million profit, +91%); "Other" ($6,792 million, $707 million profit) groups Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics. U.S. revenue $252,639 million vs $1,705 million international.
- Physician-practice services are now a core growth bet: through The Specialty Alliance (multi-specialty MSO, about 76% owned) it bought Solaris Health (urology, ~$1.9 billion, November 2025), after GI Alliance ($2.8 billion), Urology America and ION; Navista is the oncology MSO, which took a $184 million goodwill impairment.
- Heavy concentration: CVS Health was 28% of FY2026 revenue (22% of gross trade receivables); the five largest customers 43%; members of Vizient and Premier GPOs 29%; the five largest suppliers' products 39% of revenue. Red Oak Sourcing, the generics venture with CVS Health, runs through June 2029.
- Cash and capital: operating cash flow $5.2 billion; $1.9 billion on Solaris, $1.4 billion of buybacks, $649 million capex, $491 million dividends; cash $4.9 billion at year end; new $5.0 billion buyback authorisation (August 4, 2026); FY2027 capex expected at about $700 million, mainly manufacturing and distribution infrastructure and technology.
- Tariffs: about $200 million of IEEPA tariffs paid since February 2025 (mostly GMPD); after the Supreme Court ruling a ~$200 million refund receivable was booked, with a net ~$100 million Q4 benefit after amounts owed back to customers. Generic drugs could face 100% tariffs from 2028 and 200% from 2029 under a presidential statement.
- Key risks: drug-pricing policy (Inflation Reduction Act price caps, most-favored-nation order, branded-drug tariffs), generics program volatility, customer concentration, MSO-specific regulation (Oregon law and proposals restricting corporate ownership of physician practices), opioid settlements ($4.3 billion accrued, payments mostly through 2038), EtO sterilisation rules and cyber-attacks.
- Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance (news release, Form 8-K exhibit 99.1)
- Q4 FY2026 (quarter to June 30, 2026): revenue $63.7 billion (+6%), GAAP operating earnings $729 million (+70%), non-GAAP operating earnings $935 million (+30%), GAAP diluted EPS $1.70 (+70%), non-GAAP diluted EPS $2.91 (+40%), or $2.60 (+25%) excluding a one-time $0.31 IEEPA tariff refund benefit.
- Full FY2026: revenue $254.2 billion (+14%), non-GAAP operating earnings $3.6 billion (+30%), non-GAAP EPS $11.26 (+37%; $10.95, +33%, ex-IEEPA refund); operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion.
- Q4 Pharmaceutical and Specialty Solutions: revenue $58.8 billion (+6%), segment profit $645 million (+21%) on brand and specialty products and generics.
- Q4 GMPD: revenue $3.1 billion (-2%), segment profit $150 million vs $70 million, mainly from the IEEPA tariff refund ($100 million one-time net operating benefit).
- Q4 Other (Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics): revenue $1.7 billion (+7%), profit $183 million (+14%).
- FY2027 guidance: non-GAAP EPS $12.40 to $12.60 (+13% to +15% on the ex-IEEPA base); Pharma revenue +3% to 5%, profit +8% to 11%; GMPD revenue +2% to 4%, profit $200-220 million; Other revenue +11% to 13%, profit +15% to 18%; ~$1 billion buybacks, ~$700 million capex, adjusted free cash flow $3.5-4.0 billion.
- Highlights: $1.4 billion of FY2026 buybacks; $5.0 billion added to the buyback authorisation (total $6.4 billion); new $4.0 billion revolver; long-term renewal of the Kroger distribution contract; Indianapolis distribution center with robotics opening in 2027; tuck-ins of Strive Medical (completed) and AdaptHealth's Diabetes Health business (announced).
- Cardinal Health Q4 fiscal 2026 earnings call transcript (Jason Hollar, Aaron Alt)
- Hollar's four-year scorecard: from $5.07 EPS and $2.3 billion adjusted free cash flow in fiscal '22 to $11.26 EPS and $5 billion in fiscal '26, with $7 billion returned to shareholders over four years and six strategic acquisitions; "We have simplified our strategy, our structure and how we operate."
- FY2027 guidance of 13%-15% EPS growth ($12.40-$12.60) sits above the reconfirmed 12%-14% long-term target; Pharma profit +8% to 11%, with announced M&A adding 2 to 3 points.
- Specialty grew "over 25%" in fiscal 2026; planning now assumes double-digit, nearer the historical mid-teens. Biopharma Solutions is on track for $1 billion by '28 with 20+% growth; the 3PL now exclusively services nearly half the cell and gene market, and a new Innovative Care Pharmacy for cell and gene therapies opened in LaVergne, Tennessee.
- MSOs: large in GI and urology yet "a very small percentage of the market"; strategy is to expand MSOs and the services they provide.
- GMPD: $150 million Q4 profit, $50 million excluding the $100 million IEEPA refund; FY27 profit $200-220 million; Cardinal Health brand growing mid-single digits for six quarters; long-term renewal of GMPD's largest customer. A protracted Iran conflict (fuel, resins) would push GMPD to the low end.
- Other businesses: theranostics growing nearly 30% in the quarter and PET over 20%; at-Home fill rate nearly 99%; Strive Medical and AdaptHealth's diabetes business add 2 points of profit growth.
- On IRA, 340B and fee pressure: "we do not see our role changing, and we do not believe our compensation should change"; aggregate margin about 1%.
- Cardinal Health Q3 fiscal 2026 earnings call transcript (Jason Hollar, Aaron Alt)
- Q3 FY2026 (to March 2026): revenue up 11% to $61 billion, operating earnings up 18% to $956 million, non-GAAP EPS $3.17 (+35%), helped by a multi-year tax benefit of about $0.35.
- Pharma revenue +11% to $56.1 billion, profit +18% to $784 million; GLP-1s added 6 points to revenue growth, offset by 6 points from IRA WAC price cuts; distribution economics were kept intact by contract renegotiations.
- Specialty growing over 20% and expected to exceed $50 billion of revenue in fiscal 2026; oncology over 30%. A $184 million Navista goodwill impairment reflects a pivot to the equity model of oncology MSOs, not a change in MSO strategy.
- M&A priorities: autoimmune and urology, bolt-ons onto existing platforms; The Specialty Alliance now in 33 states after three more tuck-ins.
- GMPD: profit fell to $25 million on tariffs; Cardinal Health brand grew over 5% in the U.S. and at least mid-single digits for five consecutive quarters; potential IEEPA refund of about $200 million, roughly half to be passed back to customers.
- Other businesses: revenue +31% to $1.7 billion, profit +34% to $179 million; ADS integration added nearly 1,000 employees and nearly 500,000 patients; Actinium-225 capacity expansion for theranostics; a new Sacramento distribution center.
- FY2026 non-GAAP EPS guidance raised to $10.70-$10.80; Hollar on fees: "We have 1% margins" and "we fully demand to be paid the same amount going into the future."
- Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health (news release, Form 8-K exhibit 99.1)
- On October 1, 2026 Cardinal Health signed a binding Letter of Intent to extend its existing distribution agreement with CVS Health through June 30, 2032, keeping the current scope of distribution services.
- CEO Jason Hollar: "We value our long-standing partnership with CVS Health and look forward to continuing to bring our best-in-class capabilities together to serve their customers."
- With the renewal, the company reaffirmed FY2027 non-GAAP EPS guidance of 13% to 15% growth ($12.40 to $12.60) and its 12% to 14% long-term non-GAAP EPS growth rate.
- Further updates may come on the first quarter earnings call on November 5, 2026.
- The company describes itself as a distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory products, a home-health and direct-to-patient supplier, an operator of nuclear pharmacies and a provider of performance and data solutions.
Questions about Cardinal Health
What does Cardinal Health do?
Cardinal Health distributes pharmaceuticals and medical products in the US, makes Cardinal Health brand medical products, and runs physician-practice MSOs, nuclear pharmacies, home supply and freight management businesses.
What is Cardinal Health's revenue?
Revenue was $254.2 billion in the fiscal year to June 30, 2026, up 14%, of which Pharma contributed $234,833 million.
How many employees does Cardinal Health have?
About 63,900 at June 30, 2026, of whom about 18,100 outside the US and 2,700 healthcare providers.
Who leads Cardinal Health?
Jason Hollar has been CEO since September 2022 and Aaron Alt CFO since February 2023; Deborah Weitzman leads Pharma and Stephen Mason leads GMPD.
What is Cardinal Health's strategy?
It is growing specialty, biopharma services and physician-practice MSOs, expanding its higher-margin Other businesses, and growing Cardinal Health brand products, while targeting 12% to 14% long-term EPS growth.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)